Breast cancer is the most common cancer worldwide. The occurrence of breast cancer is
associated with many risk factors, including genetic and hereditary predisposition. Breast …

Developing guidelines for the diagnosis and treatment of common cancers in China based
on the evidence-based practice, the availability of diagnosis and treatment products, and the …

Background Patients with human epidermal growth factor receptor 2 (HER2)-positive
advanced breast cancer and primary resistance to trastuzumab have a poor clinical outcome …

CDK4/6 inhibitors have shown a synergistic effect with anti-HER2 therapy in hormone
receptor (HR)-positive and HER2-positive breast cancer (BC). In this phase 2 study …

Background There is an increasing need for developing effective therapies for managing
intracranial disease in patients with human epidermal growth factor receptor 2-positive …

Purpose: Despite accumulating evidence on dual blockade of HER2 for locally advanced
HER2-positive breast cancer, no robust evidence supports the addition of pyrotinib to …

Breast cancer is the most common cancer in women and the second leading cause of
cancer‐related deaths after lung cancer. Metastasis of the central nervous system is a …

Brain metastases occur in almost one-third of adult patients with solid tumor malignancies
and lead to considerable patient morbidity and mortality. The rising incidence of brain …

The role of pyrotinib in the treatment of HER2-positive metastatic breast cancer (MBC) has
been well-established. This multicenter, single-arm phase II trial (NCT03876587) aimed to …

HER2 is highly expressed in a variety of malignant tumors and affects the prognosis of
patients, making it a highly sensitive target for cancer therapy. Since the approval of the first …